Grandise

Grandise is an oral prescription medication that contains the active ingredient granisetron. It is marketed in the European Union and is supplied as a tablet (strength not specified). Granisetron belongs to the 5‑HT3 receptor antagonist class and works by blocking serotonin receptors in the chemoreceptor trigger zone and gastrointestinal tract to reduce nausea and vomiting. Grandise is available only with a doctor’s prescription in clinical practice.

Grandise is indicated for the prevention of nausea and vomiting associated with chemotherapy and postoperative recovery, and may be used in other settings where serotonin-mediated emesis is expected.

- Prevention of acute chemotherapy‑induced nausea and vomiting (CINV) in adult patients. - Prevention of delayed CINV occurring more than 24 hours after chemotherapy. - Prevention of postoperative nausea and vomiting (PONV) following general anesthesia. - Adjunctive therapy for radiation‑induced nausea when other antiemetics are insufficient. - Use in clinical protocols that require a selective 5‑HT3 antagonist for emesis control.

The safety profile of Grandise reflects the typical effects observed with 5‑HT3 receptor antagonists, most of which are mild and reversible, while rare serious events may require medical attention.

Common: - Mild to moderate headache, often transient. - Constipation that resolves without treatment. - Diarrhea occurring intermittently during therapy. - General fatigue or drowsiness. - Dry mouth sensation during treatment.

Serious: - Allergic reactions such as rash, itching, swelling, or hives. - Severe dizziness or fainting episodes requiring evaluation. - Rare cardiac arrhythmias, including ventricular ectopy. - QT interval prolongation on electrocardiogram, especially with other QT‑prolonging drugs. - Serious hypersensitivity reactions like anaphylaxis (very rare).

When prescribing Grandise, clinicians should consider several precautionary measures to ensure safe and effective use in diverse patient populations.

- Use caution in patients with known hypersensitivity to granisetron or other 5‑HT3 antagonists. - Assess cardiac history, especially in those with prolonged QT interval or electrolyte disturbances. - Adjust dose or monitor closely in patients with hepatic impairment. - Evaluate renal function, although dose adjustment is typically not required. - Avoid use during pregnancy and lactation unless benefits outweigh potential risks. - Monitor for signs of severe constipation or bowel obstruction. - Consider drug interactions that may increase QT prolongation risk.

Granisetron may interact with other medications, influencing its efficacy or increasing the risk of adverse cardiac events.

Avoid: - Concurrent use with other QT‑prolonging agents (e.g., certain antiarrhythmics, antipsychotics, macrolide antibiotics) should be avoided. - Combination with other 5‑HT3 antagonists, which can lead to additive serotonergic blockade, is not recommended.

Use with caution: - Co‑administration with CYP3A4 inhibitors or inducers, which may alter granisetron plasma levels. - Use alongside drugs that affect electrolyte balance (e.g., diuretics) due to potential QT prolongation. - Concomitant use with opioids, as both may increase the risk of constipation. - Administration with other antiemetics should be monitored for additive effects. - Patients on multiple QT‑prolonging drugs require ECG monitoring.